title: The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
abstract: BACKGROUND
  Because the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma (STS) had not been evaluated previously in a large-scale cohort, the authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with relapsed STS. This was a retrospective study based on the collection of real-life, postmarketing surveillance data.
  
  
  METHODS
  Patients received pazopanib with the objective of treating local recurrence (n = 20), metastasis (n = 104), and both (n = 32). The patient median age was 53.8 years. The primary objective of this study was to clarify the efficacy of pazopanib for patients with STS.
  
  
  RESULTS
  The median treatment duration was 28.7 weeks, and the average dose intensity of pazopanib was 609 mg. Adverse events occurred in 127 patients (81.4%). In addition to the main common toxicities, such as hypertension and liver disorder, pneumothorax (n = 11) and thrombocytopenia (n = 16) also were observed. The median progression-free survival for all patients was 15.4 weeks. The median progression-free survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 18.6 weeks, 16.4 weeks, 15.3 weeks, and 8 weeks, respectively. The median survival for all patients was 11.2 months. The median survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 20.1 months, 10.6 months, 9.5 months, and 7.3 months, respectively.
  
  
  CONCLUSIONS
  There were apparent differences in the efficacy of pazopanib treatment among histologic types of STS. Pazopanib treatment is a new treatment option; however, adverse events like pneumothorax and thrombocytopenia, which did not occur frequently in the PALETTE study (pazopanib for metastatic soft-tissue sarcoma), should be taken into consideration. Cancer 2016;122:1408-16. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
authors.affiliation: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Nakamura
authors.affiliation: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Matsumine
authors.affiliation: Division of Orthopedic Surgery, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kawai
authors.affiliation: Department of Orthopedic Surgery, Osaka General Medical Center, Osaka, Japan.
authors.forename: Nobuhito
authors.initials: N
authors.lastname: Araki
authors.affiliation: Department of Orthopedic Surgery and Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Goto
authors.affiliation: Division of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Yonemoto
authors.affiliation: Department of Orthopedic Surgery, Aichi Cancer Center, Nagoya, Japan.|Department of Physical Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Hideshi
authors.initials: H
authors.lastname: Sugiura
authors.affiliation: Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishida
authors.affiliation: Department of Orthopedic Surgery, Hokkaido Cancer Center, Hokkaido, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hiraga
authors.affiliation: Department of Orthopedic Surgery, Nara Medical University, Nara, Japan.
authors.forename: Kanya
authors.initials: K
authors.lastname: Honoki
authors.affiliation: Department of Orthopedic Surgery, University of Toyama, Toyama, Japan.
authors.forename: Taketoshi
authors.initials: T
authors.lastname: Yasuda
authors.affiliation: Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
authors.forename: Shogen
authors.initials: S
authors.lastname: Boku
authors.affiliation: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Sudo
authors.affiliation: Department of Orthopedic Surgery, Osaka National Hospital, Osaka, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ueda
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D018572:Disease-Free Survival; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007191:Indazoles; D007564:Japan / Q000453:epidemiology; D007890:Leiomyosarcoma / Q000188:drug therapy / Q000401:mortality; D008080:Liposarcoma / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D009442:Neurilemmoma / Q000188:drug therapy / Q000401:mortality; D011030:Pneumothorax / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D013584:Sarcoma, Synovial / Q000188:drug therapy / Q000401:mortality; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
keywords: efficacy; pazopanib; progression-free survival; soft tissue sarcoma; toxicity